Nicotinamide dinucleotide (nad) detection and quantification
AssigneesThe Scripps Research Institute, Vova Ida Therapeutics
InventorsCorinne LASMÉZAS, Minghai ZHOU
Life of this patent
Estimating the term…
Abstract
Methods of preventing disease or treating a subject likely to develop or having a neurodegenerative, degenerative or metabolic disease include administration of nicotinamide dinucleotide (NAD) modulating agents. Compositions include one or more agents which increase or decrease NAD in vivo or in vitro.
Claims21
A method of detecting and quantifying nicotinamide dinucleotide (NAD) in a biological sample, comprising:
- protecting NAD in the biological sample using an inhibitor of NAD degradation;
- optionally disrupting the biological sample;
- optionally clarifying the biological sample to obtain a clarified sample;
- optionally fractionating the biological sample;
- collecting the biological sample;
- and
- measuring NAD;
- thereby, detecting and quantifying nicotinamide dinucleotide (NAD) in the biological sample.
A method of identifying candidate neuroprotective or disease-modifying therapeutic agents comprising contacting a cell or biological sample with a candidate agent, measuring the nicotinamide dinucleotide (NAD) levels in the cell or biological samples as compared to controls and determining whether NAD is modulated in response to the agent.
Dependencies are inferred from the claim text.